General description
Hydroxycarbamide (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.
INN
Hydroxycarbamide
ATC codes
Medicine type
Chemical agent
EML status history
First added in 2009
(TRS
958)
for
Chronic myeloid leukaemia, not elsewhere classified
Added in 2009
(TRS
958)
for
Squamous cell carcinoma of oropharynx
Added in 2011
(TRS
965)
for
Other specified sickle cell disorders or other haemoglobinopathies
Removed in 2015
(TRS
994)
for
Squamous cell carcinoma of oropharynx
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Section
Other medicines for haemoglobinopathies
- Oral > Solid: 200 mg; 500 mg; 1 g